Skip to content

Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3)

Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05126862
Enrollment
43
Registered
2021-11-19
Start date
2021-12-10
Completion date
2023-07-09
Last updated
2024-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington Disease, Parkinson Disease

Keywords

Anxiety, Interpretation bias, Cognitive bias modification

Brief summary

The purpose of this study is conduct a pilot open trial of a web-based cognitive bias modification intervention to reduce anxiety symptoms in persons with Huntington's disease and persons with Parkinson's disease.

Detailed description

After being informed about the study and giving informed consent, participants will enroll in a pilot open trial of MindTrails, a web-based cognitive bias modification intervention. Participants will complete five, 20-minute MindTrails training sessions over five weeks. Additionally, assessments of anxiety, interpretation bias, and other related outcomes will be completed at baseline, week 3, week 5, and 2 months following the last training session. Participants will each complete a semi-structured interview to provide qualitative feedback about their experiences with MindTrails and anxiety.

Interventions

BEHAVIORALMindTrails

MindTrails is a web-based cognitive bias modification intervention. Training sessions are designed to encourage cognitive flexibility through repeated practice assigning benign resolutions to ambiguous, anxiety-provoking situations.

Sponsors

National Center for Advancing Translational Sciences (NCATS)
CollaboratorNIH
University of Virginia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Two single groups will be recruited: one including participants with Huntington's disease and the other including participants with Parkinson's disease.

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Huntington's disease or Parkinson's disease * Age 21 or older * Has anxiety symptoms (NeuroQoL Anxiety short form \>12)

Exclusion criteria

* Unable to read and understand English * Previously diagnosed with dementia * Not located in the USA

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Participants Completing at Least 50% of the MindTrails SessionsBetween baseline and week 5Proportion of participants completing at least 50% of the MindTrails sessions (defined as proportion of participants who completed outcome assessments for at least 2 of the 3 timepoints measured during the intervention: baseline, week 3, and week 5)
Participant Perceptions of Perceived Benefits and Limitations of MindTrailsAfter completion of the intervention (week 5)All participants in each arm were invited to complete a semi-structured interview to assess their experience with the intervention or barriers to beginning or completing the intervention. Interviews were transcribed, and separate codebooks were developed for PD and HD transcripts. Each transcript was coded by 2 coders, and any disagreements were resolved by a third coder. Frequency of overlapping codes under the Experiences completing MindTrails theme for each group (PD and HD) are reported here.

Countries

United States

Participant flow

Participants by arm

ArmCount
Experimental: MindTrails Pilot in Parkinson's Disease
This intervention involves completion of five, 20-minute MindTrails online training sessions over five weeks.
22
Experimental: MindTrails Pilot in Huntington's Disease
This intervention involves completion of five, 20-minute MindTrails online training sessions over five weeks.
21
Total43

Baseline characteristics

CharacteristicExperimental: MindTrails Pilot in Huntington's DiseaseTotalExperimental: MindTrails Pilot in Parkinson's Disease
Age, Continuous48.95 years
STANDARD_DEVIATION 11.81
56.67 years
STANDARD_DEVIATION 13.69
64.05 years
STANDARD_DEVIATION 11.2
Education
Associate's Degree
1 Participants5 Participants4 Participants
Education
Bachelor's
6 Participants12 Participants6 Participants
Education
Doctorate/PhD
1 Participants4 Participants3 Participants
Education
High School
3 Participants5 Participants2 Participants
Education
Master's
1 Participants5 Participants4 Participants
Education
Some College
9 Participants12 Participants3 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants6 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
17 Participants36 Participants19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
21 Participants42 Participants21 Participants
Region of Enrollment
United States
21 participants43 participants22 participants
Sex: Female, Male
Female
15 Participants24 Participants9 Participants
Sex: Female, Male
Male
6 Participants19 Participants13 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 220 / 21
other
Total, other adverse events
0 / 220 / 21
serious
Total, serious adverse events
0 / 220 / 21

Outcome results

Primary

Participant Perceptions of Perceived Benefits and Limitations of MindTrails

All participants in each arm were invited to complete a semi-structured interview to assess their experience with the intervention or barriers to beginning or completing the intervention. Interviews were transcribed, and separate codebooks were developed for PD and HD transcripts. Each transcript was coded by 2 coders, and any disagreements were resolved by a third coder. Frequency of overlapping codes under the Experiences completing MindTrails theme for each group (PD and HD) are reported here.

Time frame: After completion of the intervention (week 5)

Population: All participants in each arm were invited to complete a semi-structured interview; 14 PD participants and 10 HD participants completed interviews.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailscompleted it on phone3 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailseasy to navigate/ straight-forward13 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsparticipant baseline characteristics influence experience positively4 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsinteresting/ engaging5 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsneeded caregiver assistance1 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsneutral experience with MindTrails2 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsparticipant baseline characteristics influence experience negatively4 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsdid not enjoy MindTrails0 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailscompleted on computer3 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsdifficulty with and/or did not like forced response choice5 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailspositive experience/ enjoyed MindTrails7 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsredundancy4 Participants
Experimental: MindTrails Pilot in Parkinson's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsdid not need help to complete12 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsredundancy2 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsdid not need help to complete9 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsneeded caregiver assistance1 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailscompleted it on phone1 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailscompleted on computer3 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsparticipant baseline characteristics influence experience positively4 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsparticipant baseline characteristics influence experience negatively5 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailspositive experience/ enjoyed MindTrails4 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailseasy to navigate/ straight-forward10 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsinteresting/ engaging2 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsneutral experience with MindTrails2 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsdid not enjoy MindTrails1 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseParticipant Perceptions of Perceived Benefits and Limitations of MindTrailsdifficulty with and/or did not like forced response choice3 Participants
Primary

Proportion of Participants Completing at Least 50% of the MindTrails Sessions

Proportion of participants completing at least 50% of the MindTrails sessions (defined as proportion of participants who completed outcome assessments for at least 2 of the 3 timepoints measured during the intervention: baseline, week 3, and week 5)

Time frame: Between baseline and week 5

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Experimental: MindTrails Pilot in Parkinson's DiseaseProportion of Participants Completing at Least 50% of the MindTrails Sessions14 Participants
Experimental: MindTrails Pilot in Huntington's DiseaseProportion of Participants Completing at Least 50% of the MindTrails Sessions14 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026